T-cell lymphoma

229 EPSTEIN-BARR VIRUS DNA IN PERIPHERAL BLOOD AND EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE

K. Luttbj, 1 M. Yamaguchi, 1 R. Suzuki, 1 K. Takada, 1 Y. Harabuchi, 1 H. Gomyo, 1 T. Kuroki, 1 M. Okamoto, 1 J. Szuymiwa, 1 S. Nakamura, 1 K. Kawa, 1 K. Oshimi, 1
1NK-cell Tumor Study Group, NKTSG, Tokyo, Japan

Background: Peripheral blood of patients with extranodal NK/T-cell lymphoma, nasal type (ENKL) contains fragmented Epstein-Barr virus (EBV) DNA. Measurement of the circulating viral DNA load has been reported to be useful for diagnosis, monitoring and prognostication of the disease. However, there are two different subjects for analysis, plasma and mononuclear cells (MNC). It remains unclear which are more useful target.

Materials and Methods: To evaluate clinical significance of peripheral blood EBV-DNA copy number for ENKL, we conducted a prospective study to analyze EBV-DNA with high-sensitivity real-time quantitative polymerase chain-reaction (RT-qPCR). The primary endpoint was a prognostic value of EBV-DNA copy number to predict 2-year overall survival. Secondary endpoints were comparison of EBV-DNA copy number and pretreatment characteristics and prognostic capability of EBV-DNA during/after treatments. Three times of analysis, pre-treatment and post-treatment, post-treatment, at central laboratories were conducted. Interim analysis using pretreatment viral load, patient characteristics, and response to the first-line therapy is reported.

Results: From June 2007 to February 2009, 17 patients were registered. All patients were Japanese and diagnosed with ENKL. 21 male and 12 female. The median age was 56 years old, ranging from 18 to 81. There were 19 patients in stage IE, 3 stage IIIE, 21 stage III, 11 stage IV, respectively. 15 patients had B symptom and 14 had elevated serum LDH level. ECOG performance status (PS) was 0 in 17 patients, 1 in 8, 2 in 4, 3 in 2, respectively. IPI was high-intermediate/high in 11. First-line treatment included concurrent chemotherapy/RT-qPCR, followed by chemotherapy in 8 cases and chemotherapy alone in 6. All but one patient were analyzed for peripheral blood EBV-DNA copy number before treatment. Pretreatment MNC and plasma EBV-DNA were detectable in 6 and 14 patients, respectively. The maximum copy numbers were 780 copies/cell for MNC and 7100 copies/ml for plasma. Significant correlation was observed between mononuclear and plasma EBV-DNA copies (r=0.8741, p<0.0001). Plasma EBV-DNA well correlated with pretreatment clinical stage (p=0.02), presence of B-symptom (p=0.02), ECOG PS (p=0.02), serum LDH level (p=0.05), and soluble IL-2 receptor (p=0.0001), but not with regional node involvement (p=0.17), nasal vs. non-nasal-type (p=0.16), and serum C-reactive protein (p=0.29). Among 28 patients evaluable for response, 21 patients responded (CR/PR) to the first-line treatment. Mean plasma EBV-DNA copy number before treatment was significantly higher in non-responders compared to responders (1647 copies/ml vs 2645 copies/ml, p=0.012).

Conclusions: Our prospective study show pre-treatment EBV-DNA copy number in peripheral blood well correlate with clinical characteristics and response to the first-line therapy. Although plasma was more sensitive subject for analysis than MNC, clinical usefulness should be determined after examining prognostic significance.

230 CYTOKINE/CHEMOKINE EXPRESSION WITH PROTEIN ARRAYS IDENTIFIES THREE SUBSETS OF T-CELL LYMPHOMAS WITH DIFFERENT IMMUNOMYOLOGICAL PROFILES

S. Mercadal, 1 A. Martinez, 2 M. Phans, 1 L. Cocker, 1 G. Gutierrez-Garcia, 1 L. Colombo, 4 G. Gutierrez-Garcia, 1 L. Colombo, 4 G. Gutierrez-Garcia, 1 S. Mercadal, 1 A. Martinez, 2 M. Phans, 1 L. Cocker, 1 G. Gutierrez-Garcia, 1 L. Colombo, 4 G. Gutierrez-Garcia, 1
1Immunology, Hospital Clinic, Barcelona, Spain, 2Pathology, Hospital Clinic, Barcelona, Spain, 3Immunology, Hospital Clinic, Barcelona, Spain, 4Pathology, Hospital Clinic, Barcelona, Spain, 5Immunology, Hospital Clinic, Barcelona, Spain

Purpose: Recent studies suggested differential expression of NF-kB molecules among peripheral T-cell lymphomas (PTCLs), with possible prognostic relevance. We studied gene and protein expression of NF-kB related molecules in PTCL not otherwise specified (PTCL/NOS) in order to assess the expression pattern of NF-kB among PTCL/NOS, to determine the NF-kB cellu lar localisation, and to predict the prognostic relevance of NF-kB expression.

Experimental Design: We studied by genome DNA-microarrays 28 cases of PTCL/NOS and 24 samples of normal T-cells and lymphoid tissues. Furthermore, we studied by immunohistochemistry the expression and cellular localization of RELA, RELB, c-REL, p65, p50, and c-REI on tissue-microarrays containing 148 PTCL/NOS cases.

Results: First, we found differential expression of NF-kB molecules in PTCL/NOS and normal T-lymphocytes. In particular, PTCL/NOS showed down-regulation of RELA, RELB, and p65, additionally, according to the expression of several genes, but were clearly different from non-neoplastic samples. Secondly, we found that the vast majority of PTCL/NOS did express RELA, RELB, and c-REI at protein level. However, only few cases showed nuclear staining for such molecules, suggesting a non-active state of the system. Finally, we found that NF-kB molecules expression did not significantly correlate with the clinical outcome.

Conclusions: PTCL/NOS showed constant down-regulation of NF-kB pathway. Whether these abnormalities are determinant for PTCL/NOS pathogenesis should be defined in future studies.

232 GENETIC POLYMORPHISM AND PROTEIN EXPRESSION OF MOLECULAR MARKERS IN APOPTOTIC PATHWAYS IN T-CELL LYMPHOMA - A CORRELATIVE STUDY ON SUSCEPTIBILITY AND ANALYSIS OF CLINICAL FACTORS

S. Yang, 1 T. Sun, 2 J. Yao, 1 X. He, 1 D. Lin, 1 Y. Shi, 1
1Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Department of Etiology and Carcinogenesis, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Introduction: T-cell lymphoma is a rare disease with unique biological behavior and largely elusive pathogenesis.

Materials and methods: Genotypes of CASP8 were determined by PCR-RFLP in 92 patients with T-cell lymphoma and 301 frequency-matched controls. The expression of Caspase-8AA/ACBL-2 in 44 cases with peripheral T-cell lymphoma was examined with immunohistochemistry. The relationship between protein expression and clinical characteristics was analyzed.

Results: It was found that subjects with the CASP8 –652 6N ins/del genotype were at an increased risk for T-cell lymphoma (OR 1.95, 95% CI 1.13-3.31) compared with those with CASP8 –652 6N ins/ins genotype. It was observed that subjects having the –652 6N del/del genotype were at a 7.42-fold (95% CI 3.13-17.62) increased risk for T-cell lymphoma compared with those having the CASP8 –652 6N ins/ins genotype. We also investigated the association between genetic polymorphisms in Caspase 8 and B-cell lymphoma but no association was found.

Cases with a negative or weak positive expression of Caspase-8 showed a higher frequency of B symptoms (10/25 vs 1/15, P=0.030) and fever (7/25 vs 0/15, P=0.030). BCL-2 expression was associated with a higher prognostic index for PTCL-U (8/10 vs 9/27, P=0.023).

Downloaded from http://annonc.oxfordjournals.org/ by guest on May 17, 2012

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
Background: We studied the clinicopathologic features and treatment outcome of peripheral T-cell lymphoma (PTCL). Patients and methods: A total of 1,345 patients with non-Hodgkin's lymphoma were treated in the ALMS in Japan from 1998 to 2005. This study included 215 patients (15.9%) with T/NK-cell neoplasms.

Methods: Expression of two chemokine receptors, type 1 (Th1/Tc1)-associated CXCR3 and type 2 (Th2/Tc2)-associated CCR4, were examined in PTCL-U and ALK-negative ALCL cases, as well as the expression of cytotoxic molecules (CM). Subjects were 110 PTCL-U patients and 35 ALK-negative ALCL patients.

Results: CXCR3 and CCR4 were expressed in 69 (63%) and 37 (34%) of PTCL-U, and in 12 (34%) and 6 (17%) of ALK-negative ALCL, respectively. In PTCL-U, the type 1 pattern (CXCR3+/CCR4-) was predominant (52%), whereas in ALK-negative ALCL, 54% were negative (p < 0.0001). CM was expressed in 18 (17%) of PTCL-U and 51% of ALK-negative ALCL. Most (86%) of CM-positive PTCL-U showed the type 1 phenotype, whereas none presented with the type 2 pattern (CXCR3+/CCR4-). In contrast, CM-negative PTCL-U showed a heterogeneous pattern.

Conclusion: CM-positive PTCL-U is a distinct entity and should be differentiated from CM-negative PTCL-U.

235 EXPRESSION OF CHEMOKINE RECEPTORS (CXCR3 AND CCR4) AND CYTOTOXIC MOLECULES IN PERIPHERAL T-CELL LYMPHOMA, UNSPECIFIED AND ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA

N. Asano1, R. Suzuki2, K. Osahima3, F. Ishida4, Y. Kagami5, Y. Yoshino6, Y. Morihana7, S. Nakamura8

1Dept. of Clinical Laboratory, Shinshu University Hospital, Matsumoto, Japan, 2Dept. of HIST Data Management, Nagoya University, Nagoya, Japan, 3Dept. of Pathology, Kanazawa University, Kanazawa, Japan, 4Dept. of Internal Medicine, Shinshu University Hospital, Matsumoto, Japan, 5Dept. of Hematology and Hemotherapy, Aichi Cancer Center, Nagoya, Japan, 6Dept. of Pathology and Clinical Laboratories, Nagoya University, Nagoya, Japan

Background: Peripheral T cell lymphoma unspecified (PTCL-U) and ALK-negative anaplastic large cell lymphoma (ALCL) are heterogeneous categories with poor diagnostic reproducibility.

Methods: Expression of two chemokine receptors, type 1 (Th1/Tc1)-associated CXCR3 and type 2 (Th2/Tc2)-associated CCR4, were examined in PTCL-U and ALK-negative ALCL cases, as well as the expression of cytotoxic molecules (CM). Subjects were 110 PTCL-U patients and 35 ALK-negative ALCL patients.

Results: CXCR3 and CCR4 were expressed in 69 (63%) and 37 (34%) of PTCL-U, and in 12 (34%) and 6 (17%) of ALK-negative ALCL, respectively. In PTCL-U, the type 1 pattern (CXCR3+/CCR4-) was predominant (52%), whereas in ALK-negative ALCL, 54% were negative (p < 0.0001). CM was expressed in 18 (17%) of PTCL-U and 51% of ALK-negative ALCL. Most (86%) of CM-positive PTCL-U showed the type 1 phenotype, whereas none presented with the type 2 pattern (CXCR3+/CCR4-). In contrast, CM-negative PTCL-U showed a heterogeneous pattern.

Conclusion: CM-positive PTCL-U is a distinct entity and should be differentiated from CM-negative PTCL-U.

236 BCL10 PROTEIN HIGHLY CORRELATES WITH THE EXPRESSION OF PHOSPHORYLATED-P65 NF-KB AND IT IS ASSOCIATED WITH THE CLINICAL OUTCOME OF PERIPHERAL T-CELL LYMPHOMA

J. Briones1, E. Mogil2, I. Esponosa1, G. Vergara1, E. Alvarez1, R. Bordes1, J. Delgado1, J. Prat1, J. Sierra1

1Clinical Hematology, Hospital Santa Creu i Sant Pau, Barcelona, Spain

Introduction: Peripheral T-cell lymphomas (PTCL) are characterized by T-cell receptor (TCR) signaling alterations and NF-kB activation. Protein kinase C (PKC) is a family of proteins involved in signal transduction and mediates activation of the NF-kB pathway. In normal T cells, PKC-γ plays a major role in TCR-mediated activation of a novel NF-kB pathway that involves phosphorylation of p65 at Serine 536 (P-p65Ser536). BCL10 acts along the same pathway downstream of PCK 9 to activate NF-kB. We thus investigated the relationship between PCK 9, BCL10 and P-p65Ser536 status in biopsy specimens from patients with PTCL.

Patients and Methods: Paraffin-embedded tissues from 30 patients with nodal PTCL (PTCL unspecified, 21 cases; angioimmunoblastic, 3; ALCL, 6) treated with curative intention were evaluated. Expression of PCK 9, BCL10, and P-p65Ser536 proteins were assessed using immunohistochemistry.

Results: Expression of PCK 9 was detected in 22 of 30 cases (73%), BCL10 in 20 of 30 (67%), and P-p65Ser536 in 21 of 30 tumors (70%). BCL10 positive tumors were associated with PCK 9 (0.18, p = 0.0001), and P-p65Ser536 (0.19 of 21 expression (p = 0.0001). After a median follow-up of 60 months for surviving patients (range, 21-160 months), 5-year overall survival (OS) was 33%. Patients with BCL10 or P-p65Ser536 positive tumors fared better, with a 5-year OS of 48% and 43%, respectively, versus 0% for those with negative tumors (P = 0.029, and P = 0.04, respectively).

Conclusion: BCL10 expression identified a subgroup of patients within the low Ki-67 group (< 40% positive tumor cells) with a different outcome; thus, within this subgroup patients with BCL10 positive tumors had a 5-year OS of 85% while it was 0% for those with BCL10 negative tumors (P = 0.011). Multivariate analysis showed that BCL10, Ki-67, and P-p65Ser536 expression were independent factors associated with OS (P = 0.039, 0.029, and 0.050, respectively).

Conclusion: BCL10 is expressed in PTCL, correlates with PCK 9 and P-p65Ser536 NF-kB expression and it seems to be associated with better survival in PTCL.
237 COMPLETION OF PLANNED RADIOTHERAPY IS THE MOST IMPORTANT PROGNOSTIC FACTOR IN THE TREATMENT OF EARLY STAGE UPPER AERODIGESTIVE NASAL-TYPE NK/T CELL Lymphoma
S. Yap 1, W. Tham 1, S. Hee 2, S. Lim 3, R. Quek 1, L. Lim 4, L. Tan 1, M. Tao 1, S. Loong 1
1Department of Radiation Oncology, National Cancer Centre, Singapore, Singapore. 2Division of Clinical Trials & Epidemiological Sciences, National Cancer Centre, Singapore, Singapore. 3Department of Medical Oncology, National Cancer Centre, Singapore, Singapore. 4Department of Haematology, Singapore General Hospital, Singapore, Singapore. 5Department of Pathology, Singapore General Hospital, Singapore, Singapore.

Introduction: This study reviews the role of radiotherapy (RT) for this rare lymphoma.

Material & methods: A retrospective review was conducted on 34 patients with stage I-II nasal NK/T-cell lymphoma seen at our radiotherapy centre between 1996 and 2007.

Results: Nineteen had tumour involving sino-nasal complex only, 7 had involvement at both sub-sites. Twenty-three had stage I, and 11 had stage II disease. Median follow-up was 35 months. Eight did not complete RT because of clinical deterioration or systemic progression while 2 because of severe acute radiation side effects. Median dose was 50 Gy in 1.8 – 2.0 daily fractions using 6 MV photons. Twenty-five (73.5%) also had chemotherapy (CT). After commencement of CT, 3 required RT to be brought forward, due to disease progression (2) or severe side effects (2). Nineteen received early RT (after 14 cycles of CT) and 6 received late RT (after 24 cycles of CT). Median time from diagnosis to start of RT was 48 days.

Conclusions: Our data showed that completion of RT plays a significant role in maintaining high DFS. RT remains a mainstay in the treatment for early stage disease. Novel systemic agents will need to be further evaluated to improve on the results.

238 HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN NASAL NK/T CELL LYMPHOMA: A RETROSPECTIVE COMPARISON WITH NON-TRANSPLANTATION CASES IN CHINA
K. Gu1, H. Wang2, M. Wang3, H. Zhang1, Z. Song1, X. Li1, Z. Qian1, X. Hao1
1Department of Lymphoma, Tianjin Medical University Cancer Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. 2American Society of Clinical Oncology (ASCO). 3Department of Lymphoma and Myeloma, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA, Houston, United States

Introduction: Up to now, no standard therapy is clearly defined for Nasal NK/T-cell lymphoma (NNTCL). To determine the role and indications of high-dose chemotherapy supported by autologous stem cell transplantation (HDC/ASCT) in Chinese NNTCL patients, a retrospective comparison was conducted in Tianjin Medical University Cancer Hospital, China.

Material and methods: Between 1992 and 2005, among 223 patients with newly diagnosed NNTCL, 22 eligible patients receiving HDC/ASCT were studied and 91 patients given conventional chemotherapy or radiotherapy were enrolled in the study as historical controls. They all achieved complete remission (CR) or partial remission (PR) after induction therapy, followed by HDC/ASCT or consolidation therapy.

Results: With a median follow-up of 36 months (range, 2 – 180 months), 9 (40.9%) of 22 patients relapsed after 3 – 61 months after HDC/ASCT. Among the 9 patients, 6 cases (27.3%) died of disease progression. Sixty-six patients (72.5%) given conventional therapy alone had a relapse and 54 patients (59.3%) died after relapse. The median survival (CR/PR) was 19.8 months (range, 2 – 80 months) in patients who received HDC/ASCT, versus 14.9 months in patients who received conventional therapy. However, the 5-year overall survival was not statistically significant between two groups. The 5-year disease-free survival was 91.7% in patients who underwent HDC/ASCT as compared to those who did not (the estimated 5-year overall survival (OS) rate: 93.4% vs. 88.6%, P=0.141). The impact of HDC/ASCT on improving disease-specific survival and overall survival was not significant in multivariate analysis.

Conclusions: HDC/ASCT should be recommended as a highly effective primary therapy for patients with previously untreated NNTCL, especially for those with advanced disease (stage III/IV) in CR or PR status through induction therapy and with stage II and high risk prognostic factors such as B symptom and high IPI score.

239 AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN EXTRANODAL NK/T CELL LYMPHOMA: A MULTINATIONAL, MULTICENTER, MATCHED CONTROLLED STUDY
1Division of Hematology/Oncology, Samsung Medical Center, Seoul, Korea, Republic of. 2Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong. 3First Department of Internal Medicine, Fukuoka University School of Medicine, Fukuoka, Japan. 4Department of Pathology, Nagaoya University School of Medicine, Nagaoya, Japan. 5Department of Radiology and Haematology, Tohoku University School of Medicine, Sendai, Japan. 6Department of Hematology and Oncology, Chiba Cancer Center, Chiba, Japan. 7Department of Hematology, Juntendo University, Tokyo, Japan. 8Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong. 9Department of Hematology- Oncology, Korea Cancer Center Hospital, Seoul, Korea, Republic of. 10Department of Internal Medicine, Asan Medical Center, Seoul, Korea, Republic of. 11Department of Pathology, Samsung Medical Center, Seoul, Korea, Republic of. 12Department of Hematopoietic Stem Cell Transplantation Data Management, Nagaoya University School of Medicine, Nagaoya, Japan

This retrospective study analyzed the potential survival benefits of HSCT in comparison with a historical control group. 47 patients from 3 previously published series of HSCT were matched according to NK-PI risk groups (risk score 0.1 v 2.4) and disease status at transplantation with 107 patients from a historical control group for analysis. After a median follow-up duration of 116.5 months, the median survival time has not been reached for the HSCT group while it was 43.5 months for the control group (95% CI, 6.7 – 80.3, P=0.127). In patients who were in CR at the time of HSCT or of surveillance following remission, disease-specific survival rates were significantly higher in the HSCT group as compared with the control group (5-year survival rate, 87.5 vs 67.8%, P=0.027). In patients in non-CR, there were no significant difference between the HSCT and the control group (P=0.1). The impact of HSCT on survival of all patients was significantly retained at multivariate level with 2.1-fold (95% CI, 1.2 – 3.7) reduced risk of death (P=0.066). HSCT seems to confer survival benefit in pts who attained CR as post-remission consolidation therapy, especially in pts with high NKPI risk scores.
240 bis ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) AFTER NON-MYELOABLATIVE CONDITIONING FOR RELAPSED AND REFRactory T / NK-CELL LYMPHOMAS

1University of Washington and 2Fred Hutchinson Cancer Research Center, Seattle; 3City of Hope National Medical Center, Duarte; 4Stanford University, Stanford, USA; 5University of Leipzig, Leipzig, Germany; 6University of Turino, Turino, Italy

Background: Patients with relapsed/refractory T/NK-cell lymphomas have poor outcomes with few therapeutic options. Some patients with chemo-sensitive disease can be salvaged with autologous HCT. Allogeneic HCT with myeloablative conditioning is commonly offered to younger patients but treatment related mortality is high. We examined the outcomes of allogeneic HCT after non-myeloablative conditioning in this setting.

Patients and Methods: In this multi-institutional phase II trial fifteen patients received salvage therapy followed by conditioning with 2 Gy of total body irradiation and fludarabine, (30mg/m2 X 3 doses) followed by HCT from HLA-matched related (n=5) and unrelated donor (n=10) marrow. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and mycophenolate mofetil. Three patients had precurso T-cell neoplasms, 1 had blastic NK-lymphoma and 11 patients had various histologies of peripheral T-cell lymphomas. Median age of patients was 39 (range: 18 to 72) and median number of prior therapies was 4, including prior autologous SCT in 7. Four patients had progressive disease.

Results: Seven of the 15 patients are alive in CR with a median follow-up of 3.2 years. Five patients died from progressive disease, one died of GVHD and two died of other treatment related causes. Estimated 3-year overall and progression-free survivals were 47%. The incidence of acute GVHD, grade 3 and 4 acute GVHD and extensive chronic GVHD were 73%, 33% and 60%, respectively. The estimated probabilities of 3-year non-relapse and relapse mortalities were 20% and 33%, respectively.

Conclusions: Allogeneic HCT after non-myeloablative conditioning is a promising salvage option for patients with relapsed/refractory T/NK-cell lymphomas, has acceptable treatment-related mortality and extants the conventional age limitations for this approach. Results suggest that graft-vs-T-cell lymphoma activity is responsible for long-term disease control.

241 PHASE II OPEN-LABEL TRIAL OF BELINOSTAT (PXD101) IN PATIENTS WITH RECURRENT OR REFRACTORY PERIPHERAL OR CUTANEOUS T-CELL LYMPHOMA

F. Foss1, B. Pohrihan1, E. Jacobson2, K. Hyrmes2, R. Advani3, Y. Kim2, R. Bell4, A. Lerner5, C. Oeff5, P. Blum-Jensen6, M. Douc7,8
1Yale Univ., New Haven, Connecticut, 2USC Cleveland, Cleveland, Ohio, United States, 3DFCI, Boston, United States, 4NYU Med Ctr, New York, United States, 5Stanford, Stanford, United States, 6Stanford, Stanford, United States, 7Kansas City CC, Lenexa, United States, 8Boston Med Ctr, Boston, United States

Background: Belinostat is a hydroxamate pan-HDAC inhibitor with broad preclinical anti-cancer activity that is well-tolerated and has shown activity in the clinic. Methods: Global, open-label, multicenter Phase II trial that enrolled patients (pts) with peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL) who failed 3 or more prior systemic therapy. Pts received 1000 mg/m2 IV belinostat over 30-min days 1-5 of a 3-wk cycle. Primary endpoint was objective response (OR) assessed by IWG criteria for PTCL or by SWAT for CTCL. For each group a Simon 2-stage design was used with 25% target OR rate.

Results: PTCL group-14 pts (7 PTCL-unspecifed (PTCL-U), 3 anaplastic large cell lymphoma (ALCL), 2 anaplastic immunoblastic T-lymphoma, 1 T-NK, 1 subcutaneous panenclitic-like T-Lymphoma (SPTCL)) were treated for a median of 2.5 cycles (range 1-6). Of 10 evaluable pts, 2 CR (duration 18+ and 21+ wks) both in pts with PTCL-U and 4 SD (median duration 14 wks, range 7-23) in pts with PTCL-U, ALCL and NK-TCL were observed. Two pts are ongoing. CTCL group-21 pts (11 mycosis fungoides (MF), 7 Sezary syndrome (SS), 2 primary cutaneous ALCL, 1 SPTCL), 76% at Stage IV, were treated for a median of 2 cycles (range 1-6). 3 ORS in 19 evaluable pts; 1 CR (ALCL) and 2 PR (1 MF, 1 SS). Median OR duration was 17 wks (range 7-55wks); 13/18 pts (72%) with evaluable scores had a decrease in SWAT. 6/7 pts with significant pruritus had improvement. Most common (>10%) drug-related adverse events (AE) were nausea, vomiting, injection site reaction, flushing, and anorexia. Grade 3/4 drug-related AE reported in 6 pts were rash, adenymic ileus, apraxia, infection, peripheral edema, pneumonitis, pruritus, and thrombocytopenia.

Conclusions: The OR rate in both groups met the criteria for expansion and is accruing 34 pts per group. Belinostat appears well-tolerated and shows clinical activity in PTCL and CTCL.

242 CLINICAL EFFICACY AND SAFETY OF VORINOSTAT IN RELAPSED/ REFRactory CTCL

E.A. Olsen1, M. Ducu2
1Div of Dermatology & Oncology, Duke Univ Medical Center, Durham, United States, 2Dept of Dermatology, MD Anderson Cancer Center, Houston, United States

Background: Vorinostat (ZolinzaTM) is an orally active, potent inhibitor of histone deacetylase. Here we report corrobative conclusions on the clinical efficacy of vorinostat in cutaneous T-cell lymphoma (CTCL) based on the results from two completed Phase II studies.

Materials and methods: An initial study exploring various vorinostat dosing regimens and a second pivotal study using a 400 mg qd dose, enrolled patients (pts) with advanced CTCL who were refractory to and/or intolerant of other therapies. Pts in the initial study must have received 2 or 3 prior systemic therapy for CTCL compared with 2 or 2 in the pivotal study. Only those pts in the initial study that were treated with vorinostat 400 mg qd (the FDA-approved dose in CTCL) are included in the comparison. The primary endpoint in both studies was objective response rate (ORR).

Results: The two studies were similar with respect to baseline characteristics. A total of 87 pts were included in the combined analysis. At baseline, 72 had ≥ Stage IIB CTCL. ORRs were comparable between the pts taken from the initial study and the pivotal study overall (80.8% and 79.7%, respectively) and in pts with Stage IIB or higher (36.4% and 29.5%, respectively). Median time to objective response ranged from approximately 2 to 3 months; 88 and 53 days in the initial and pivotal studies, respectively. Median duration of response (DOR) was 113 days in the initial study versus in excess of 4 months (upper range: 322 days) in the pivotal study (DOR not reached, study ongoing for duration). Of particular interest was the clinically meaningful reduction in pruritus in symptomatic pts in both studies; 72.7% in the initial study and 31.9% in the pivotal study reported pruritus relief. Furthermore, complete resolution of pruritus was observed in 9.1% and 11.1% of pts, respectively. Vorinostat was associated with an acceptable safety profile and was generally well tolerated in both studies.

Conclusions: Even though required prior treatment and evaluation of response differed, response rates were similar and clinically meaningful in a substantial proportion of pts with CTCL (Stage IB and above), who had progressive, persistent, or recurrent disease subsequent to prior therapies.

243 L-ASPARGINASE IN THE TREATMENT OF EXTRA NODAL NK/ T-CELL LYMPHOMA

A. Jaccard1, F. Suau2, C. Thieblemont3, V. Collette4, J. Ziri5, A. Devidas6, E. Pellet1, R. Gachard1, O. Herrman7,1
1Hematology, CHU, Limoges, France, 2Hematology, Necker, Paris, France, 3Hematology, St-Louis, Paris, France, 4Hematology, CHU, Lille, France, 5Hematology, Languedoc, Paris, France, 6Hematology, Hospital, Corbel, France, 7Anapath, CHU, Limoges, France

Background: Extra nodal NK/T-cell lymphoma, nasal type, is an EBV-related highly aggressive disease with a poor outcome, especially when disseminated or recurrent. L-Asparaginase seems to have a particular efficacy in this disease.

Material and methods: We used this drug in 12 French centers to treat 27 patients with relapsed, refractory or disseminated nasal type NK/T-cell lymphoma. Fifteen patients were retrospectively collected and twelve patients were treated in a prospective phase II trial using L-asparaginase (Kidrolase® 6000 Ui/m2 IM at day 2, 4, 6, 8, methotrexate 3 g/m2 at day 1 and dexamethasone 40 mg at day 1 to 4 with 3 weeks cycles.

Results: There were 20 men and 7 women, median age was 55 (38 to 81), 13 were primary refractory, 12 were in relapse, 15 were in stage IV including the 2 patients treated upfront. L-asparaginase, 6000 Ui/m2 (1 to 6 courses) was given for 4 to 10 days associated with Dexamethasone 40 mg for 4 days (n=23), methotrexate 3 g/m2 (n=16) or velbe 6 mg (n=1). Six patients who had a severe anaphylactic reaction with L-asparaginase received further courses of Erwiniase® (n=3) or PEG-asparaginase (Oncaspar®) (n=3). Treatment efficacy was evident in all patients but three, 12 patients were in documented complete remission (CR) after treatment with L-asparaginase. Fourteen patients died of unrelated causes (n=5) or progression of disease (n=9). Toxicity related to L-asparaginase was mild, mainly brief leucopenia and elevation of alanine aminotransferase. Thirteen patients are still alive with a median follow-up of 14 months (1 to 49). 4 patients are in persistent CR and received high dose therapy with autologous stem cell transplant and 2 patients received irradiation after L-asparaginase treatment.

Conclusion: The efficacy of L-asparaginase to treat extra nodal NK/T-cell lymphoma must be known because of the very poor prognosis of patients with disseminated or...
CLOFARABINE IS ACTIVE IN PERIPHERAL T-CELL LYMPHOMAS: RESULTS OF THE PHASE I PORTION OF A PHASE I/II STUDY

S. Horwitz1, D. Mulford2, H. Paul1, H. Weissbrot1, A.D. Zelenetz1

1Medicine, Memorial Sloan Kettering Cancer Center, New York, United States, 2Hematology, University of Rochester, Rochester, United States

Background: Clofarabine is a nucleoside analog with increased stability and prolonged intracellular half-life. Clofarabine leads to cell death through 1) Inhibition of ribonucleotide reductase 2) inhibition of chain elongation by DNA polymerases 3) disruption of mitochondrial membranes. In trials for acute leukemia, several complete responses (CR) were seen among patients (pts) with T or NK lymphoma (TCL). To explore this activity we are conducting a phase I/II trial in TCL.

Methods: The phase I part of this study used an accelerated titration design-starting at 4 mg/m² daily for 3 consecutive days. Cycles are repeated q 3 weeks (max 8). Upon grade 2 non-heme toxicity, the dose escalation is switched to a traditional 3-6 pts / cohort design. Eligibility required a diagnosis of rel/ref TCL without standard curative options; relapse post autologous or allogeneic stem cell transplantation is permitted.

Results: To date, 11 pts have enrolled on the phase I. Histologies include: PTCL 2, HLV-1 lymphoma 2, ALK-1 negative Anaplastic Large Cell lymphoma 2, NK or NK/ TCL (NK/T) 2, Angioimmunoblastic TCL (AITL) 1, Lymphoblastic lymphoma 1. Transformed mycosis fungoides 1 pts were refractory to their last therapy. Cohorts were: 4 mg/m² n=1, 8 mg/m² n=3, 13.2 mg/m² n=3, 20 mg/m² n=3, 28 mg/m² n=1.

Gr 3-4 heme tox were neutropenia n=6, thrombocytopenia n=6, anemia n=5. Gr 3-4 drug related non-heme tox were fever and neutropenia n=2. All toxicities except thrombocytopenia in 1 pt (28 mg/m²) resolved to allow the next cycle with ≤1 week delay. Best responses were SD 5, PR 1, CR 1. 4 pts had primary progression. CR was seen in 1 pt with AITL at 8 mg/m². This pt remains in CR >9 months from end of therapy.

Conclusions: In this Phase I/II study, Clofarabine showed activity, including a durable CR at doses much lower than used for acute leukemia. This treatment has been very well tolerated in heavily pre-treated pts. DLTs have not been seen. This activity at well tolerated doses suggests a role for clofarabine in managing TCL and may be a good candidate for combination regimens.